Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Merck KGaA (OP: MKGAF)
157.83 USD  UNCHANGED
Last Price  /  Updated: 8:10 PM EDT, May 13, 2013  /  Add to My Watchlist      
View: Quote News
Blog posts about Merck KGaA
 
Pfizer-Hisun JV Launched – Analyst Blog
September 18, 2012
Pfizer (PFE) and Chinese pharmaceutical company, Zhejiang Hisun Pharmaceuticals, recently announced the launch of their joint venture (JV) – Hisun-Pfizer Pharmaceuticals Co., Ltd. The joint venture,... Read More
category Zacks , Syndicated Content
from Money Morning
(RDY) Merck KGaA to Acquire Biochrom AG
August 26, 2012
Merck KGaA (MKGAF) recently announced a definitive agreement to acquire Berlin, Germany-based... Visit StockBlogHub to view complete post. Read More
category RDY , Dr/ Reddy's Laboratories Limited , Healthcare , and 1 more.
from Stock Blog Hub
Merck KGaA to Acquire Biochrom AG – Analyst Blog
August 25, 2012
Merck KGaA (MKGAF) recently announced a definitive agreement to acquire Berlin, Germany-based Biochrom AG. Biochrom AG, which specializes in the production and marketing of cell culture media and... Read More
category Zacks , Syndicated Content
from Money Morning
(PFS) Merck KGaA’s Erbitux Drug Disappoints in Trial
July 11, 2012
Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the... Visit StockBlogHub to view complete post. Read More
category Sanofi/Aventis , LLY , Provident Financial Services Inc , and 13 more.
from Stock Blog Hub
Merck KGaA’s Erbitux Faces Hurdle
May 17, 2012
Merck KGaA (MKGAF) recently reported disappointing interim data from a late-stage study (PETACC-8) on Erbitux (cetuximab), which is being evaluated as an adjuvant treatment of stage III colon cancer.... Read More
category AZN , RHHBY , External Research , and 8 more.
from DailyMarkets.com
FDA Issues CRL For Watson’s Drug
March 01, 2012
Watson Pharmaceuticals Inc. (NYSE:WPI) along with partner Columbia Laboratories Inc. (NASDAQ:CBRX) recently announced that the US Food and Drug Administration (FDA) has issued a complete response... Read More
category MKGAF , CBRX , WPI , and 3 more.
from DailyMarkets.com
Update On Watson’s Candidate
February 15, 2012
Watson Pharmaceuticals Inc. (NYSE:WPI) along with partner Columbia Laboratories Inc. (NASDAQ:CBRX) recently announced that the latter has transferred the new drug application (NDA) for progesterone... Read More
category MKGAF , CBRX , WPI , and 3 more.
from DailyMarkets.com
MKGAF-THLD Unite For Cancer Cure
February 08, 2012
Merck KGaA (MKGAF) recently announced that it has entered into a global agreement with Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), for the development and commercialization of the latter’s... Read More
category MKGAF , THLD , Stocks , and 2 more.
from DailyMarkets.com
Label Expansion For Merck KGaA Drug
January 27, 2012
Merck KGaA(MKGAF) was recently buoyed by the news of European Commission (EC) approving its lead drug Rebif for the treatment of patients who have experienced a single demyelinating event, and are at... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Label Expansion For Merck KGaA Drug
January 27, 2012
Merck KGaA(MKGAF) was recently buoyed by the news of European Commission (EC) approving its lead drug Rebif for the treatment of patients who have experienced a single demyelinating event, and are at... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Watson’s Drug Fails To Get Support
January 23, 2012
Watson Pharmaceuticals Inc. (NYSE:WPI) and Columbia Laboratories Inc. (NASDAQ:CBRX) recently announced that the US Food and Drug Administration’s (FDA) advisory committee recommended against the... Read More
category MKGAF , CBRX , WPI , and 4 more.
from DailyMarkets.com
Sanofi’s Multiple Sclerosis Drug Disappoints
December 23, 2011
Sanofi’s (NYSE:SNY) subsidiary, Genzyme, recently announced disappointing top-line results of its phase III candidate, Aubagio (teriflunomide). Results were presented from the phase III TENERE trial,... Read More
category NVS , MKGAF , SNY , and 4 more.
from DailyMarkets.com
CHMP Recommends Merck KGaA’s Rebif
November 21, 2011
Merck KGaA (MKGAF) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of Rebif for the treatment of... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Roche’s Avastin Loses FDA’s Support
November 21, 2011
Roche Holdings Ltd. (RHHBY) has been a regular topic of discussion of late, but this time it is in the news not for positive reasons. The company announced that the US Food and Drug Administration... Read More
category RHHBY , MKGAF , Stocks , and 3 more.
from DailyMarkets.com
Sanofi’s MS Candidate Advances
November 17, 2011
Sanofi’s (NYSE:SNY) subsidiary Genzyme (acquired in April 2011) recently announced encouraging data on its phase III candidate, Lemtrada (alemtuzumab). Results were presented from the phase III CARE-MS... Read More
category MKGAF , SNY , Stocks , and 3 more.
from DailyMarkets.com
Merck KGaA Misses On EPS, Sales Up
October 28, 2011
Merck KGaA’s (MKGAF) earnings per share for the third quarter 2011 came in at $1.34, well below the Zacks Consensus Estimate of $2.30, but above the year-ago earnings of $1.29. Despite higher operating... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Merck KGaA Washes Hands Of PD Drug
October 24, 2011
Merck KGaA (MKGAF) recently announced that it will return all rights for safinamide to Newron Pharmaceuticals S.p.A. Merck KGaA had purchased exclusive worldwide rights to develop, manufacture and... Read More
category ONTY , MKGAF , Stocks , and 2 more.
from DailyMarkets.com
Merck KGaA, Ono Pharma Collaborate
October 14, 2011
In a bid to strengthen its multiple sclerosis and cancer franchises, Merck KGaA (MKGAF) entered into a couple of agreements with Japanese pharma company, Ono Pharmaceutical Co. Ltd. According to the... Read More
category ONTY , MKGAF , Stocks , and 2 more.
from DailyMarkets.com
Two Novartis Drugs Cleared In Japan
October 05, 2011
Swiss pharma giant Novartis (NYSE:NVS) received a shot in the arm with two of its popular drugs receiving regulatory approval in Japan. The Ministry of Health, Labor and Welfare (MHLW) cleared Gilenya... Read More
category NVS , MKGAF , Stocks , and 3 more.
from DailyMarkets.com
Merck KGaA Buys Rights To MS Drug
September 26, 2011
Merck KGaA (MKGAF) recently announced the acquisition of exclusive worldwide development and commercialization rights to multiple sclerosis (MS) candidate PI-2301. The candidate was developed by... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Costs Spoil Merck KGaA’s EPS
July 29, 2011
Merck KGaA’s (MKGAF) second quarter 2011 results fell short of the Zacks Consensus Estimate on all fronts, although it reported higher year-over-year revenues. Earnings per share for the second quarter... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Watson To Market Antares’ OAB Drug
July 12, 2011
Watson Pharmaceuticals Inc. (NYSE:WPI) recently announced that it has entered into a licensing agreement with Antares Pharma Inc. (AIS) for the commercialization of Antares Pharma’s topical oxybutynin... Read More
category AIS , MKGAF , CBRX , and 4 more.
from DailyMarkets.com
(MS) Merck KGaA Seeks Rebif Extension
July 07, 2011
Merck KGaA (MKGAF) recently filed a marketing application with the European Medicines Agency (EMA) in its endeavor to expand the label of Rebif, its multiple sclerosis (MS) therapy. The company is... Read More
category MS , Morgan Stanley , TEVA , and 5 more.
from Stock Blog Hub
Merck KGaA Seeks Rebif Extension
July 07, 2011
Merck KGaA (MKGAF) recently filed a marketing application with the European Medicines Agency (EMA) in its endeavor to expand the label of Rebif, its multiple sclerosis (MS) therapy. The company is... Read More
category MKGAF , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Watson-Columbia Drug’s NDA Accepted
June 29, 2011
Watson Pharmaceuticals Inc. (NYSE:WPI) along with Columbia Laboratories Inc. (NASDAQ:CBRX) recently announced that the latter’s New Drug Application (NDA) for Prochieve (progesterone gel) has been... Read More
category MKGAF , CBRX , WPI , and 4 more.
from DailyMarkets.com
(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug
June 23, 2011
Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to... Read More
category ELN , MS , Morgan Stanley , and 9 more.
from Stock Blog Hub
Merck KGaA To Withdraw MS Drug
June 23, 2011
Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to... Read More
category ELN , MKGAF , TEVA , and 4 more.
from DailyMarkets.com
Pfizer Announces Deals
June 03, 2011
Pfizer Inc. (NYSE:PFE) recently entered into a development and commercialization agreement with biopharma company Clovis Oncology, Inc. for Pfizer’s oral and IV Poly (ADP-ribose) polymerase (PARP)... Read More
category NVS , MKGAF , Stocks , and 3 more.
from DailyMarkets.com
Merck KGaA Beats, Revises Outlook
April 29, 2011
Merck KGaA (MKGAF) posted first quarter 2011 earnings of $2.78 per share, beating the Zacks Consensus Estimate of $2.13 and the year-ago earnings of $2.01. Higher revenues helped boost the quarter’s... Read More
category External Research , Contributor , LLY , and 7 more.
from DailyMarkets.com
CRL For Merck KGaA MS Drug
March 04, 2011
Merck KGaA (MKGAF) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for its new drug application (NDA) for cladribine. Merck KGaA is seeking... Read More
category ELN , Australia , TEVA , and 7 more.
from DailyMarkets.com
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here